Rabbit anti-Pig Legumain Polyclonal Antibody | anti-LGMN antibody

Anti-Legumain Antibody, Rabbit Polyclonal

Cat. Num. AAA8112473

• Reactivity: Pig
• Applications: Western Blot, Immunoprecipitation
• Purity: Protein A & Antigen Affinity
• Synonyms: Legumain; Polyclonal Antibody; Anti-Legumain Antibody; Rabbit Polyclonal; Legumain/LGMN Antibody; Rabbit PAb; Antigen Affinity Purified; legumain; anti-LGMN antibody

• Host: Rabbit
• Reactivity: Pig
• Clonality: Polyclonal
• Isotype: Rabbit IgG
• Specificity: Sus scrofa (Pig) Legumain/LGMN
• Purity/Purification: Protein A & Antigen Affinity
• Form/Format: Liquid; 0.2um filtered solution in PBS

• Applicable Applications for anti-LGMN antibody: Western Blot (WB), Immunoprecipitation (IP)
• Application Notes: WB: 1:500-1:2000; IP: 4-6uL/mg of lysate
• Immunogen: Recombinant Sus scrofa (Pig) Legumain/LGMN Protein
• Conjugation: Unconjugated
• Preparation: Produced in rabbits immunized with purified, recombinant Sus scrofa (Pig) Legumain/LGMN. Legumain/LGMN specific IgG was purified by Sus scrofa (Pig) Legumain/LGMN affinity chromatography.
• Preparation and Storage: This antibody can be stored at 2-8 degree C for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20 degree C to -80 degree C. Preservative-Free. Avoid repeated freeze-thaw cycles.

Immunoprecipitation (IP)

(susLGMN was immunoprecipitated using:Lane A:0.5 mg Hela Whole Cell Lysate2 uL anti-susLGMN rabbit polyclonal antibody and 15 ul of 50 % Protein G agarose.Primary antibody:Anti-susLGMN rabbit polyclonal antibody,at 1:200 dilution Secondary antibody:Clean-Blot IP Detection Reagent (HRP) at 1:1000 dilution Developed using the DAB staining technique.Performed under reducing conditions.Predicted band size: 49 kDaObserved band size: 39 kDa)

Western Blot (WB)

(Anti-LGMN rabbit polyclonal antibody at 1:500 dilution.Lane A: Mouse kidney tissue lysateLysates/proteins at 30 ug per lane.SecondaryGoat Anti-Rabbit IgG H&L (Dylight800) at 1/10000 dilution.Developed using the Odyssey technique. Performed under reducing conditions.Predicted band size:49 kDaObserved band size:35 kDa)

Related Product Information for anti-LGMN antibody

The Mammalian Legumain, also known as LGMN, also called asparaginyl endopeptidase (AEP), is a cysteine protease belonging to peptidase family C13 with strict specificity for hydrolysis of asparaginyl bonds. Known previously only from plants and invertebrates, Legumain is discovered as a lysosomal endopeptidase in mammals. Mammalian Legumain is a cysteine endopeptidase, inhibited by iodoacetamide and maleimides, but unaffected by compound E64. The Mammalian Legumain is involved in the processing of bacterial peptides and endogenous proteins for MHC class II presentation in the lysosomal/endosomal systems. Legumain has been observed to be highly expressed in several types of solid tumors. It was demonstrated in membrane-associated vesicles concentrated at the invadopodia of tumor cells and on cell surfaces where it colocalized with integrins. Legumain was demonstrated to activate progelatinase A. Cells overexpressing Legumain possessed increased migratory and invasive activity in vitro and adopted an invasive and metastatic phenotype in vivo, inferring significance of Legumain in tumor invasion and metastasis. Also, Legumain is expressed in both murine and human atherosclerotic lesions. The macrophage-specific expression of Legumain in vivo and the ability of Legumain to induce chemotaxis of monocytes and endothelial cells in vitro suggest that Legumain may play a functional role in atherogenesis.

References

Schwarz G, et al. (2002) Characterization of legumain. Biol Chem. 383(11): 1813-6.Liu C, et al. (2003) Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res. 63(11): 2957-64.Murthy RV, et al. (2005) Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. Clin Cancer Res. 11(6): 2293-9.Gawenda J, et al. (2007) Legumain expression as a prognostic factor in breast cancer patients. Breast Cancer Res Treat. 102(1): 1-6.Clerin V, et al. (2007) Expression of the cysteine protease legumain in vascular lesions and functional implications in atherogenesis. Atherosclerosis. 201(1): 53-66.Lew?"n S, et al. (2008) A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis. Cancer Immunol Immunother. 57(4): 507-15.

NCBI and Uniprot Product Information

• Protein Family: Legumain